Abbott Earnings: What to Expect Wednesday

Abbott Laboratories has been independent from its AbbVie spinoff for more than a year now, and its nutrition and diagnostics segments have given it plenty of growth.

Jan 21, 2014 at 2:00PM

Abbott Labs (NYSE:ABT) will release its quarterly report on Wednesday, and investors have been pleased with the company's success as an independent company, bidding its share price to all-time record highs. Even though the company no longer has its branded-pharmaceutical business, Abbott earnings could continue to grow even as it vies against Mead Johnson Nutrition (NYSE:MJN) in nutritional products and Johnson & Johnson's (NYSE:JNJ) Ortho Clinical unit in diagnostics.

The split-up of Abbott Labs and AbbVie has led to a big change for Abbott, which has had to go without the sales of AbbVie's blockbuster drug Humira. Yet Abbott has done a good job of moving forward with its growth opportunities, benefiting from its ability to focus on promising areas like its nutritional unit, which is its largest business by revenue. Moreover, diagnostics have started to gain traction as well, even as J&J has sought to divest itself of its diagnostics unit to seek faster growth in pharmaceuticals. Let's take an early look at what's been happening with Abbott Labs over the past quarter and what we're likely to see in its report.

Source: Abbott Labs.

Stats on Abbott Labs

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$5.72 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance. * Adjusted for AbbVie spinoff.

Can Abbott earnings keep growing?
In recent months, analysts have made very slight reductions to their views on Abbott earnings, cutting a penny per share from their fourth-quarter estimates and $0.02 per share from their full-year 2014 projections. The stock, though, has kept moving higher, rising almost 18% since mid-October.

The biggest portion of the gains in Abbott Labs stock came right after its third-quarter earnings report. Abbott's diagnostics business produced double-digit percentage revenue growth, outpacing Johnson & Johnson's Ortho unit with everything from molecular diagnostics and point-of-care services to core lab sales rising steadily. Sales growth in nutrition and medical devices was less encouraging, but higher gross margins helped Abbott make more from the revenue it brought in. Earnings per share beat Abbott's own guidance, and a hefty 57% jump in the company's dividend brought its dividend yield up to 2.5%.

Abbott has made substantial strategic moves to shore up some of its business segments. In the medical-device market, Abbott's purchase Idev last year gave it more exposure to some of the fastest-growing areas among medical devices, with stent technology making Abbott a much stronger competitor against J&J's Cordis unit and other players in the field. Similarly, Abbott's purchase of OptiMedica last summer should help it in the laser-cataract area. Integrating all these strategic combinations will be essential to Abbott's long-term success.

One interesting opportunity that it appears Abbott will pass up is the chance to buy Johnson & Johnson's Ortho diagnostics unit. J&J received a private-equity offer earlier this month for the unit, and while the terms of the offer allow J&J to get rival bids, Abbott seems content to stand pat with its own successful business for the time being.

Also, Abbott needs to pay close attention to quality-control issues in its nutritional segment. Fallout from a product recall in China hasn't kept Abbott's nutritional division from growing, but it has slowed that growth down, and with huge amounts of competition from international giants like Nestle and Danone as well as Mead Johnson Nutrition, Abbott can't afford any further mistakes.

In the Abbott earnings report, watch to see whether revenue from the nutritional business perks back up after its third-quarter sluggishness. Moreover, if diagnostics continue to do well, Abbott could start to see accelerating earnings growth in 2014 and beyond.

The #1 way to LOSE your wealth without ever even knowing it...

You've fought hard to build wealth for you and your family. Yet one all-too-common pitfall could completely derail your dreams before you even know it. That's why a company The Economist hails as "an ethical oasis" has isolated five simple questions you must answer to ensure that your financial future is really secure.

Can you answer YES to all five of these eye-opening questions?

Click here to find out -- before it's too late!


Click here to add Abbott Labs to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers